SensoDetect AB
SensoDetect AB
10/31/2025 | Press release | Distributed by Public on 10/31/2025 05:25
SensoDetect: SensoDetect AB Confirms receipt of license payments and announces successful installation and testing of AI software in China
Press release from Companies
Publicerat: 2025-10-31 12:22:28
SensoDetect AB: SensoDetect AB Confirms receipt of license payments and announces successful installation and testing of AI software in China
SensoDetect AB (Spotlight Stock Market: SDET) is pleased to confirm that all license payments from its joint venture, Beijing Mind Exploration Medical Technology Co., Ltd., have been received in full and on time. This marks another significant milestone in the collaboration and commercialization of SensoDetect's BERA 4.2 system and its next-generation AI-driven diagnostic platform in China.
The company further announces that the AI software has now been successfully installed and activated within the joint venture's operational framework in Beijing. The first testing series has shown very promising results, confirming that the system can now perform the entire neurophysiological test in less than 5 minutes and 30 seconds, a substantial improvement in speed and efficiency.
Even though the system processes an extremely large amount of neurophysiological data, the AI calculations can be completed in under 10 seconds - either locally on the device or through secure cloud computation. This represents a major technological leap forward, significantly improving scalability, accessibility, and reliability for both clinical and research use.
"We are very pleased to confirm that all financial commitments from our Chinese partners have been fulfilled in full and that the AI system is now live and performing beyond expectations," says Per-Anders Hedin, CEO of SensoDetect AB. "The early test results are highly encouraging and demonstrate the strength of our technology to redefine clinical diagnostics by making it faster, smarter, and more efficient than ever before."
The AI module represents the next major evolution of SensoDetect's proprietary BERA (Brainstem Evoked Response Audiometry) technology, combining advanced signal processing with modern machine learning. With the system now operational, the joint venture will move forward with extended clinical validation, NMPA regulatory preparations, and scaling for production.
This progress follows the recently completed initial investment round in the joint venture, strengthening both its financial and technological base for a large-scale launch in the Chinese market.
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
[email protected]
SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.
More info at https://www.sensodetect.com/
CisionLink
Läs som PDF
SensoDetect AB published this content on October 31, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 31, 2025 at 11:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]